Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

7.14 (USD) • At close December 23, 2024
Bedrijfsnaam Monte Rosa Therapeutics, Inc.
Symbool GLUE
Munteenheid USD
Prijs 7.14
Beurswaarde 438,658,038
Dividendpercentage 0%
52-weken bereik 3.21 - 12.4
Industrie Biotechnology
Sector Healthcare
CEO Dr. Markus Warmuth M.D.
Website https://www.monterosatx.com

An error occurred while fetching data.

Over Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven

Vergelijkbare Aandelen

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

14.25 USD

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

2.24 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

62.82 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

4.77 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

3.94 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

6.09 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

76.79 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

9.25 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

19.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)